2025 Ranking of the World’s Top 13 IVD Corporations

By Mark Terry | From the Volume XXXII, No. 13 – September 15, 2025 Issue

BASED ON PUBLICLY-REPORTED 2024 DIAGNOSTICS-RELATED REVENUE, four in vitro diagnostics (IVD) companies continue to dominate the global market, as they have for the last two years: Thermo Fisher Scientific, Roche, Danaher, and Abbott Laboratories. The top 13 companies …

Read More

---

At ADLM 2025, Spotlight Shines on Relationships

By Scott Wallask | From the Volume XXXII, No. 11 – August 4, 2025 Issue

CEO SUMMARY: At the ADLM conference, a new industry survey about the dynamic relationship between medical laboratories, physicians, and patients presented a strong argument for labs taking the lead in communicating and being more accessible to their colleagues. A troubleso…

Read More

---

Fast, $17.5B Deal Lands Waters Corp. in IVD Market

By Janette Wider | From the Volume XXXII, No. 11 – August 4, 2025 Issue

WHEN BECTON DICKINSON  (BD) ANNOUNCED ITS INTENT to spin off its in vitro diagnostics (IVD) and life sciences units in February, few observers expected a deal to close just five months later. But now that such an agreement has occurred as of July 14, the buy…

Read More

---

Lab Stakeholders Discuss PAMA Reform

By Stephen Beale | From the Volume XXXII, No. 10 – July 14, 2025 Issue

CEO SUMMARY: Medical labs need to brace for more action to counter pending test reimbursement rate cuts under PAMA. Although labs have received PAMA reprieves from Congress over the last few years, laboratory associations argue that Congress needs to vote on long-term reforms rather than …

Read More

---

News Briefs on Alzheimer’s Detection

By Scott Wallask | From the Volume XXXII, No. 9 – June 23, 2025 Issue

FDA-cleared IVD could replace scans There has been a significant amount of activity in recent weeks as it concerns tests to detect Alzheimer’s disease. Clinical labs and neuropathologists will want to keep a cl…

Read More

---

Economic, Tech Changes Drive Lab Concerns

By Robert Michel | From the Volume XXXII, No. 7 – May 12, 2025 Issue

CEO SUMMARY: Uncertainty around tariffs, future regulations, and artificial intelligence (AI) defined the mood at the 2025 Executive War College, where nearly 1,000 lab leaders gathered. Speakers warned of how stagnant healthcare spending could trickle down to labs. Meanwh…

Read More

---

As 23andMe Faces Bankruptcy, Home Testing Shows Warts

By Robert Michel | From the Volume XXXII, No. 7 – May 12, 2025 Issue

HIGH-STAKES DRAMA SURROUNDING 23ANDME’S BANKRUPTCY—including CEO Anne Wojcicki resigning to try to bid for the company she cofounded and state prosecutors urging caution about the data privacy of the company’s customers—brings up a fundamental question regarding d…

Read More

---

BD Will Sell Diagnostics Arm but Retain Vacutainer Brand

By Robert Michel | From the Volume XXXII, No. 6 – April 21, 2025 Issue

LESS THAN TWO MONTHS AFTER ANNOUNCI…

Read More

---

Global IVD Companies Issue Fourth Quarter 2024 Earnings

By Robert Michel | From the Volume XXXII, No. 5 – March 31, 2025 Issue

OVERALL, IN VITRO DIAGNOSTICS (IVD) COMPANIES REPORTED A MIXED BAG of financial results for the quarter ending Dec. 31, 2024, with Becton, Dickinson and Company, Abbott Laboratories, and Siemens Healthineers showing the most momentum based on r…

Read More

---

Global IVD Companies Issue Third Quarter 2024 Earnings

By Robert Michel | From the Volume XXXI, No. 16 – November 25, 2024 Issue

HERE IS A SUMMARY OF THE THIRD QUARTER FINANCIAL PERFORMANCE of t…

Read More

---